Zevra Therapeutics, Inc.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, VRTX has a market cap of 123.2B. Regarding current trading prices, ZVRA is priced at $12.02, while VRTX trades at $479.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas VRTX's P/E ratio is -125.89. In terms of profitability, ZVRA's ROE is -2.01%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, ZVRA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, REGN has a market cap of 59.4B. Regarding current trading prices, ZVRA is priced at $12.02, while REGN trades at $559.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas REGN's P/E ratio is 14.22. In terms of profitability, ZVRA's ROE is -2.01%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ZVRA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ZVRA is priced at $12.02, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ZVRA's ROE is -2.01%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ZVRA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ALNY has a market cap of 42.1B. Regarding current trading prices, ZVRA is priced at $12.02, while ALNY trades at $322.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ALNY's P/E ratio is -153.69. In terms of profitability, ZVRA's ROE is -2.01%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, ZVRA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ARGX has a market cap of 34.4B. Regarding current trading prices, ZVRA is priced at $12.02, while ARGX trades at $563.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ARGX's P/E ratio is 34.37. In terms of profitability, ZVRA's ROE is -2.01%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, ZVRA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, BNTX has a market cap of 27.4B. Regarding current trading prices, ZVRA is priced at $12.02, while BNTX trades at $113.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas BNTX's P/E ratio is -30.31. In terms of profitability, ZVRA's ROE is -2.01%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, ZVRA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, RPRX has a market cap of 20.3B. Regarding current trading prices, ZVRA is priced at $12.02, while RPRX trades at $36.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas RPRX's P/E ratio is 14.74. In terms of profitability, ZVRA's ROE is -2.01%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, ZVRA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ZVRA is priced at $12.02, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ZVRA's ROE is -2.01%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, ZVRA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, SMMT has a market cap of 19.2B. Regarding current trading prices, ZVRA is priced at $12.02, while SMMT trades at $25.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas SMMT's P/E ratio is -76.19. In terms of profitability, ZVRA's ROE is -2.01%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, ZVRA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ZVRA is priced at $12.02, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ZVRA's ROE is -2.01%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, ZVRA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, INCY has a market cap of 13.6B. Regarding current trading prices, ZVRA is priced at $12.02, while INCY trades at $70.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas INCY's P/E ratio is 351.65. In terms of profitability, ZVRA's ROE is -2.01%, compared to INCY's ROE of +0.01%. Regarding short-term risk, ZVRA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, UTHR has a market cap of 13.5B. Regarding current trading prices, ZVRA is priced at $12.02, while UTHR trades at $300.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas UTHR's P/E ratio is 11.96. In terms of profitability, ZVRA's ROE is -2.01%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ZVRA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, GMAB has a market cap of 13.5B. Regarding current trading prices, ZVRA is priced at $12.02, while GMAB trades at $21.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas GMAB's P/E ratio is 12.86. In terms of profitability, ZVRA's ROE is -2.01%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, ZVRA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MRNA has a market cap of 13.3B. Regarding current trading prices, ZVRA is priced at $12.02, while MRNA trades at $34.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MRNA's P/E ratio is -3.93. In terms of profitability, ZVRA's ROE is -2.01%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ZVRA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ZVRA is priced at $12.02, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ZVRA's ROE is -2.01%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ZVRA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, EXEL has a market cap of 12.3B. Regarding current trading prices, ZVRA is priced at $12.02, while EXEL trades at $45.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas EXEL's P/E ratio is 20.62. In terms of profitability, ZVRA's ROE is -2.01%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, ZVRA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, ZVRA is priced at $12.02, while BMRN trades at $58.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas BMRN's P/E ratio is 21.79. In terms of profitability, ZVRA's ROE is -2.01%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, ZVRA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ASND has a market cap of 10.6B. Regarding current trading prices, ZVRA is priced at $12.02, while ASND trades at $176.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ASND's P/E ratio is -25.79. In terms of profitability, ZVRA's ROE is -2.01%, compared to ASND's ROE of +1.91%. Regarding short-term risk, ZVRA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ZVRA is priced at $12.02, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ZVRA's ROE is -2.01%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ZVRA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, ZVRA is priced at $12.02, while VRNA trades at $104.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas VRNA's P/E ratio is -52.42. In terms of profitability, ZVRA's ROE is -2.01%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, ZVRA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, ZVRA is priced at $12.02, while BBIO trades at $46.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas BBIO's P/E ratio is -13.00. In terms of profitability, ZVRA's ROE is -2.01%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, ZVRA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ZVRA is priced at $12.02, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ZVRA's ROE is -2.01%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, ZVRA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, TECH has a market cap of 8.5B. Regarding current trading prices, ZVRA is priced at $12.02, while TECH trades at $54.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas TECH's P/E ratio is 65.55. In terms of profitability, ZVRA's ROE is -2.01%, compared to TECH's ROE of +0.06%. Regarding short-term risk, ZVRA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ZVRA is priced at $12.02, while BPMC trades at $129.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas BPMC's P/E ratio is -51.73. In terms of profitability, ZVRA's ROE is -2.01%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, ZVRA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ZVRA is priced at $12.02, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas CERE's P/E ratio is -16.47. In terms of profitability, ZVRA's ROE is -2.01%, compared to CERE's ROE of -0.43%. Regarding short-term risk, ZVRA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, ZVRA is priced at $12.02, while ROIV trades at $11.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ROIV's P/E ratio is -15.42. In terms of profitability, ZVRA's ROE is -2.01%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, ZVRA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, ZVRA is priced at $12.02, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, ZVRA's ROE is -2.01%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, ZVRA is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, ZVRA is priced at $12.02, while CORT trades at $72.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas CORT's P/E ratio is 62.67. In terms of profitability, ZVRA's ROE is -2.01%, compared to CORT's ROE of +0.20%. Regarding short-term risk, ZVRA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, RVMD has a market cap of 7.2B. Regarding current trading prices, ZVRA is priced at $12.02, while RVMD trades at $38.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas RVMD's P/E ratio is -9.60. In terms of profitability, ZVRA's ROE is -2.01%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, ZVRA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, AMRN has a market cap of 7.1B. Regarding current trading prices, ZVRA is priced at $12.02, while AMRN trades at $17.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas AMRN's P/E ratio is -3.92. In terms of profitability, ZVRA's ROE is -2.01%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, ZVRA is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, HALO has a market cap of 7.1B. Regarding current trading prices, ZVRA is priced at $12.02, while HALO trades at $57.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas HALO's P/E ratio is 15.33. In terms of profitability, ZVRA's ROE is -2.01%, compared to HALO's ROE of +1.22%. Regarding short-term risk, ZVRA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MDGL has a market cap of 7B. Regarding current trading prices, ZVRA is priced at $12.02, while MDGL trades at $314.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MDGL's P/E ratio is -17.65. In terms of profitability, ZVRA's ROE is -2.01%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, ZVRA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, JAZZ has a market cap of 6.8B. Regarding current trading prices, ZVRA is priced at $12.02, while JAZZ trades at $112.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas JAZZ's P/E ratio is 15.28. In terms of profitability, ZVRA's ROE is -2.01%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, ZVRA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, ZVRA is priced at $12.02, while IONS trades at $42.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas IONS's P/E ratio is -14.18. In terms of profitability, ZVRA's ROE is -2.01%, compared to IONS's ROE of -0.92%. Regarding short-term risk, ZVRA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ZVRA is priced at $12.02, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas RETA's P/E ratio is -66.29. In terms of profitability, ZVRA's ROE is -2.01%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ZVRA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, TGTX has a market cap of 6B. Regarding current trading prices, ZVRA is priced at $12.02, while TGTX trades at $37.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas TGTX's P/E ratio is 150.68. In terms of profitability, ZVRA's ROE is -2.01%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, ZVRA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, RYTM has a market cap of 5.7B. Regarding current trading prices, ZVRA is priced at $12.02, while RYTM trades at $89.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas RYTM's P/E ratio is -31.82. In terms of profitability, ZVRA's ROE is -2.01%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, ZVRA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ZVRA is priced at $12.02, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ZVRA's ROE is -2.01%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ZVRA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ZVRA is priced at $12.02, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ZVRA's ROE is -2.01%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ZVRA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, AXSM has a market cap of 5.4B. Regarding current trading prices, ZVRA is priced at $12.02, while AXSM trades at $110.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas AXSM's P/E ratio is -18.82. In terms of profitability, ZVRA's ROE is -2.01%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, ZVRA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, NUVL has a market cap of 5.4B. Regarding current trading prices, ZVRA is priced at $12.02, while NUVL trades at $82.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas NUVL's P/E ratio is -18.57. In terms of profitability, ZVRA's ROE is -2.01%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, ZVRA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, ZVRA is priced at $12.02, while TLX trades at $16.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas TLX's P/E ratio is 178.44. In terms of profitability, ZVRA's ROE is -2.01%, compared to TLX's ROE of +0.14%. Regarding short-term risk, ZVRA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, ZVRA is priced at $12.02, while CRSP trades at $59.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas CRSP's P/E ratio is -13.14. In terms of profitability, ZVRA's ROE is -2.01%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, ZVRA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ALKS has a market cap of 5B. Regarding current trading prices, ZVRA is priced at $12.02, while ALKS trades at $30.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ALKS's P/E ratio is 14.51. In terms of profitability, ZVRA's ROE is -2.01%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, ZVRA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, PCVX has a market cap of 4.7B. Regarding current trading prices, ZVRA is priced at $12.02, while PCVX trades at $36.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas PCVX's P/E ratio is -9.09. In terms of profitability, ZVRA's ROE is -2.01%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, ZVRA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ZVRA is priced at $12.02, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ZVRA's ROE is -2.01%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, ZVRA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ADMA has a market cap of 4.4B. Regarding current trading prices, ZVRA is priced at $12.02, while ADMA trades at $18.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ADMA's P/E ratio is 21.99. In terms of profitability, ZVRA's ROE is -2.01%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, ZVRA is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, ZVRA is priced at $12.02, while CYTK trades at $36.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas CYTK's P/E ratio is -6.91. In terms of profitability, ZVRA's ROE is -2.01%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, ZVRA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, ZVRA is priced at $12.02, while KRYS trades at $149.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas KRYS's P/E ratio is 36.03. In terms of profitability, ZVRA's ROE is -2.01%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, ZVRA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ZVRA is priced at $12.02, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas OPT's P/E ratio is -1.52. In terms of profitability, ZVRA's ROE is -2.01%, compared to OPT's ROE of +2.60%. Regarding short-term risk, ZVRA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, AKRO has a market cap of 4.1B. Regarding current trading prices, ZVRA is priced at $12.02, while AKRO trades at $52.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas AKRO's P/E ratio is -13.86. In terms of profitability, ZVRA's ROE is -2.01%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, ZVRA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ZVRA is priced at $12.02, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ZVRA's ROE is -2.01%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ZVRA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MRUS has a market cap of 4.1B. Regarding current trading prices, ZVRA is priced at $12.02, while MRUS trades at $55.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MRUS's P/E ratio is -13.25. In terms of profitability, ZVRA's ROE is -2.01%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, ZVRA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, SLNO has a market cap of 4B. Regarding current trading prices, ZVRA is priced at $12.02, while SLNO trades at $80.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas SLNO's P/E ratio is -16.94. In terms of profitability, ZVRA's ROE is -2.01%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, ZVRA is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, ZVRA is priced at $12.02, while PTCT trades at $49.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas PTCT's P/E ratio is 7.61. In terms of profitability, ZVRA's ROE is -2.01%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, ZVRA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MTSR has a market cap of 3.8B. Regarding current trading prices, ZVRA is priced at $12.02, while MTSR trades at $36.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MTSR's P/E ratio is -14.34. In terms of profitability, ZVRA's ROE is -2.01%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, ZVRA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ACLX has a market cap of 3.8B. Regarding current trading prices, ZVRA is priced at $12.02, while ACLX trades at $68.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ACLX's P/E ratio is -23.05. In terms of profitability, ZVRA's ROE is -2.01%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, ZVRA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, RNA has a market cap of 3.8B. Regarding current trading prices, ZVRA is priced at $12.02, while RNA trades at $31.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas RNA's P/E ratio is -10.49. In terms of profitability, ZVRA's ROE is -2.01%, compared to RNA's ROE of -0.27%. Regarding short-term risk, ZVRA is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, ZVRA is priced at $12.02, while ZLAB trades at $34.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ZLAB's P/E ratio is -13.62. In terms of profitability, ZVRA's ROE is -2.01%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, ZVRA is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ZVRA is priced at $12.02, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ZVRA's ROE is -2.01%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ZVRA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ZVRA is priced at $12.02, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ZVRA's ROE is -2.01%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ZVRA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, ZVRA is priced at $12.02, while ACAD trades at $22.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ACAD's P/E ratio is 16.10. In terms of profitability, ZVRA's ROE is -2.01%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, ZVRA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, LEGN has a market cap of 3.7B. Regarding current trading prices, ZVRA is priced at $12.02, while LEGN trades at $39.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas LEGN's P/E ratio is -33.66. In terms of profitability, ZVRA's ROE is -2.01%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, ZVRA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, SRRK has a market cap of 3.6B. Regarding current trading prices, ZVRA is priced at $12.02, while SRRK trades at $38.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas SRRK's P/E ratio is -14.95. In terms of profitability, ZVRA's ROE is -2.01%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, ZVRA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, AAPG has a market cap of 3.5B. Regarding current trading prices, ZVRA is priced at $12.02, while AAPG trades at $40.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas AAPG's P/E ratio is -54.43. In terms of profitability, ZVRA's ROE is -2.01%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, ZVRA is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ZVRA is priced at $12.02, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ZVRA's ROE is -2.01%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, ZVRA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, VKTX has a market cap of 3.5B. Regarding current trading prices, ZVRA is priced at $12.02, while VKTX trades at $31.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas VKTX's P/E ratio is -26.97. In terms of profitability, ZVRA's ROE is -2.01%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, ZVRA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, ZVRA is priced at $12.02, while PTGX trades at $52.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas PTGX's P/E ratio is 67.77. In terms of profitability, ZVRA's ROE is -2.01%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, ZVRA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, ZVRA is priced at $12.02, while KYMR trades at $45.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas KYMR's P/E ratio is -14.52. In terms of profitability, ZVRA's ROE is -2.01%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, ZVRA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MLTX has a market cap of 3.1B. Regarding current trading prices, ZVRA is priced at $12.02, while MLTX trades at $48.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MLTX's P/E ratio is -21.29. In terms of profitability, ZVRA's ROE is -2.01%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, ZVRA is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, CRNX has a market cap of 3B. Regarding current trading prices, ZVRA is priced at $12.02, while CRNX trades at $31.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas CRNX's P/E ratio is -8.42. In terms of profitability, ZVRA's ROE is -2.01%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, ZVRA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, IMVT has a market cap of 3B. Regarding current trading prices, ZVRA is priced at $12.02, while IMVT trades at $17.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas IMVT's P/E ratio is -6.41. In terms of profitability, ZVRA's ROE is -2.01%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, ZVRA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, RARE has a market cap of 2.9B. Regarding current trading prices, ZVRA is priced at $12.02, while RARE trades at $31.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas RARE's P/E ratio is -5.32. In terms of profitability, ZVRA's ROE is -2.01%, compared to RARE's ROE of -1.86%. Regarding short-term risk, ZVRA is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, NAMSW has a market cap of 2.9B. Regarding current trading prices, ZVRA is priced at $12.02, while NAMSW trades at $10.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas NAMSW's P/E ratio is N/A. In terms of profitability, ZVRA's ROE is -2.01%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, ZVRA is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, ZVRA is priced at $12.02, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MORF's P/E ratio is -14.88. In terms of profitability, ZVRA's ROE is -2.01%, compared to MORF's ROE of -0.22%. Regarding short-term risk, ZVRA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, ZVRA is priced at $12.02, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MOR's P/E ratio is -12.64. In terms of profitability, ZVRA's ROE is -2.01%, compared to MOR's ROE of -1.84%. Regarding short-term risk, ZVRA is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, ZVRA is priced at $12.02, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas KDNY's P/E ratio is -12.47. In terms of profitability, ZVRA's ROE is -2.01%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, ZVRA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, ZVRA is priced at $12.02, while CPRX trades at $21.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas CPRX's P/E ratio is 13.91. In terms of profitability, ZVRA's ROE is -2.01%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, ZVRA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, ZVRA is priced at $12.02, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MYOV's P/E ratio is -14.05. In terms of profitability, ZVRA's ROE is -2.01%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, ZVRA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, ZVRA is priced at $12.02, while MIRM trades at $53.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas MIRM's P/E ratio is -32.90. In terms of profitability, ZVRA's ROE is -2.01%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, ZVRA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, ARWR has a market cap of 2.6B. Regarding current trading prices, ZVRA is priced at $12.02, while ARWR trades at $18.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas ARWR's P/E ratio is -15.22. In terms of profitability, ZVRA's ROE is -2.01%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, ZVRA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, IBRX has a market cap of 2.5B. Regarding current trading prices, ZVRA is priced at $12.02, while IBRX trades at $2.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas IBRX's P/E ratio is -5.05. In terms of profitability, ZVRA's ROE is -2.01%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, ZVRA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, ZVRA is priced at $12.02, while XENE trades at $32.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas XENE's P/E ratio is -10.24. In terms of profitability, ZVRA's ROE is -2.01%, compared to XENE's ROE of -0.32%. Regarding short-term risk, ZVRA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, NAMS has a market cap of 2.5B. Regarding current trading prices, ZVRA is priced at $12.02, while NAMS trades at $22.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas NAMS's P/E ratio is -11.96. In terms of profitability, ZVRA's ROE is -2.01%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, ZVRA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, APLS has a market cap of 2.5B. Regarding current trading prices, ZVRA is priced at $12.02, while APLS trades at $19.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas APLS's P/E ratio is -10.84. In terms of profitability, ZVRA's ROE is -2.01%, compared to APLS's ROE of -1.00%. Regarding short-term risk, ZVRA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, LGND has a market cap of 2.4B. Regarding current trading prices, ZVRA is priced at $12.02, while LGND trades at $124.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas LGND's P/E ratio is -17.14. In terms of profitability, ZVRA's ROE is -2.01%, compared to LGND's ROE of -0.16%. Regarding short-term risk, ZVRA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, ZVRA is priced at $12.02, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas PRVB's P/E ratio is -16.43. In terms of profitability, ZVRA's ROE is -2.01%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, ZVRA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, ZVRA is priced at $12.02, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas LBPH's P/E ratio is -26.66. In terms of profitability, ZVRA's ROE is -2.01%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, ZVRA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, ZVRA is priced at $12.02, while APGE trades at $38.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas APGE's P/E ratio is -10.67. In terms of profitability, ZVRA's ROE is -2.01%, compared to APGE's ROE of -0.19%. Regarding short-term risk, ZVRA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, ZVRA is priced at $12.02, while AGIO trades at $39.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas AGIO's P/E ratio is 3.43. In terms of profitability, ZVRA's ROE is -2.01%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, ZVRA is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, RXRX has a market cap of 2.3B. Regarding current trading prices, ZVRA is priced at $12.02, while RXRX trades at $5.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas RXRX's P/E ratio is -3.40. In terms of profitability, ZVRA's ROE is -2.01%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, ZVRA is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, ZVRA is priced at $12.02, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas DICE's P/E ratio is -21.91. In terms of profitability, ZVRA's ROE is -2.01%, compared to DICE's ROE of +0.56%. Regarding short-term risk, ZVRA is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, DNLI has a market cap of 2.2B. Regarding current trading prices, ZVRA is priced at $12.02, while DNLI trades at $15.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas DNLI's P/E ratio is -5.75. In terms of profitability, ZVRA's ROE is -2.01%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, ZVRA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, BEAM has a market cap of 2.2B. Regarding current trading prices, ZVRA is priced at $12.02, while BEAM trades at $22.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas BEAM's P/E ratio is -4.78. In terms of profitability, ZVRA's ROE is -2.01%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, ZVRA is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, VCYT has a market cap of 2.2B. Regarding current trading prices, ZVRA is priced at $12.02, while VCYT trades at $27.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas VCYT's P/E ratio is 65.52. In terms of profitability, ZVRA's ROE is -2.01%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, ZVRA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, ZVRA is priced at $12.02, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas CALT's P/E ratio is -22.73. In terms of profitability, ZVRA's ROE is -2.01%, compared to CALT's ROE of -1.67%. Regarding short-term risk, ZVRA is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, ZVRA is priced at $12.02, while KNSA trades at $28.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas KNSA's P/E ratio is -120.58. In terms of profitability, ZVRA's ROE is -2.01%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, ZVRA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, ZVRA is priced at $12.02, while VCEL trades at $41.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas VCEL's P/E ratio is 824.80. In terms of profitability, ZVRA's ROE is -2.01%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, ZVRA is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for ZVRA.

ZVRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZVRA stands at 656.7M. In comparison, CGON has a market cap of 2.1B. Regarding current trading prices, ZVRA is priced at $12.02, while CGON trades at $27.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZVRA currently has a P/E ratio of -6.19, whereas CGON's P/E ratio is -18.30. In terms of profitability, ZVRA's ROE is -2.01%, compared to CGON's ROE of -0.17%. Regarding short-term risk, ZVRA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for ZVRA.